Niu M, Liu Y, Shi J, Chen R, Zhang S, Li C
Biomolecules. 2024; 14(5).
PMID: 38785979
PMC: 11118191.
DOI: 10.3390/biom14050572.
Rizzuti B, Abian O, Velazquez-Campoy A, Neira J
Molecules. 2023; 28(22).
PMID: 38005300
PMC: 10673428.
DOI: 10.3390/molecules28227578.
Gasparoli L, Virely C, Tsakaneli A, Che N, Edwards D, Bartram J
Haematologica. 2023; 109(4):1069-1081.
PMID: 37794795
PMC: 10985450.
DOI: 10.3324/haematol.2023.283613.
Ivanenkov Y, Kukushkin M, Beloglazkina A, Shafikov R, Barashkin A, Ayginin A
Molecules. 2023; 28(3).
PMID: 36770991
PMC: 9919490.
DOI: 10.3390/molecules28031325.
Ali S, A Khan H, Irfan O, Samad A, Mirza Y, Awan M
Cureus. 2017; 9(6):e1401.
PMID: 28856073
PMC: 5573341.
DOI: 10.7759/cureus.1401.
Molecular dynamic simulation insights into the normal state and restoration of p53 function.
Fu T, Min H, Xu Y, Chen J, Li G
Int J Mol Sci. 2012; 13(8):9709-9740.
PMID: 22949826
PMC: 3431824.
DOI: 10.3390/ijms13089709.
Udu deficiency activates DNA damage checkpoint.
Lim C, Chong S, Jiang Y
Mol Biol Cell. 2009; 20(19):4183-93.
PMID: 19656853
PMC: 2754932.
DOI: 10.1091/mbc.e09-02-0109.
Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2.
Saha A, Murakami M, Kumar P, Bajaj B, Sims K, Robertson E
J Virol. 2009; 83(9):4652-69.
PMID: 19244339
PMC: 2668485.
DOI: 10.1128/JVI.02408-08.
Updates on p53: modulation of p53 degradation as a therapeutic approach.
Dey A, Verma C, Lane D
Br J Cancer. 2008; 98(1):4-8.
PMID: 18182973
PMC: 2359710.
DOI: 10.1038/sj.bjc.6604098.
Effects of in vitro fertilization and embryo culture on TRP53 and Bax expression in B6 mouse embryos.
Chandrakanthan V, Li A, Chami O, ONeill C
Reprod Biol Endocrinol. 2006; 4:61.
PMID: 17118206
PMC: 1687191.
DOI: 10.1186/1477-7827-4-61.
DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation.
Okamoto K, Kashima K, Pereg Y, Ishida M, Yamazaki S, Nota A
Mol Cell Biol. 2005; 25(21):9608-20.
PMID: 16227609
PMC: 1265801.
DOI: 10.1128/MCB.25.21.9608-9620.2005.
Reversible aggregation plays a crucial role on the folding landscape of p53 core domain.
Ishimaru D, Lima L, Maia L, Lopez P, Ano Bom A, Valente A
Biophys J. 2004; 87(4):2691-700.
PMID: 15298872
PMC: 1304688.
DOI: 10.1529/biophysj.104.044685.
pRB induces Sp1 activity by relieving inhibition mediated by MDM2.
Johnson-Pais T, Degnin C, Thayer M
Proc Natl Acad Sci U S A. 2001; 98(5):2211-6.
PMID: 11226218
PMC: 30117.
DOI: 10.1073/pnas.051415898.
A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control.
Li L, Liao J, Ruland J, Mak T, Cohen S
Proc Natl Acad Sci U S A. 2001; 98(4):1619-24.
PMID: 11172000
PMC: 29306.
DOI: 10.1073/pnas.98.4.1619.
Molecular pathogenesis of oral squamous carcinoma.
Williams H
Mol Pathol. 2000; 53(4):165-72.
PMID: 11040937
PMC: 1186964.
DOI: 10.1136/mp.53.4.165.
Colorectal carcinomas arising in the hyperplastic polyposis syndrome progress through the chromosomal instability pathway.
Hawkins N, Gorman P, Tomlinson I, Bullpitt P, Ward R
Am J Pathol. 2000; 157(2):385-92.
PMID: 10934143
PMC: 1850120.
DOI: 10.1016/S0002-9440(10)64551-8.
Evidence that dynamin-2 functions as a signal-transducing GTPase.
Fish K, Schmid S, Damke H
J Cell Biol. 2000; 150(1):145-54.
PMID: 10893263
PMC: 2185575.
DOI: 10.1083/jcb.150.1.145.
The p53 tumor suppressor protein does not regulate expression of its own inhibitor, MDM2, except under conditions of stress.
Mendrysa S, Perry M
Mol Cell Biol. 2000; 20(6):2023-30.
PMID: 10688649
PMC: 110819.
DOI: 10.1128/MCB.20.6.2023-2030.2000.
Species-specific regulation of alternative splicing in the C-terminal region of the p53 tumor suppressor gene.
Laverdiere M, Beaudoin J, Lavigueur A
Nucleic Acids Res. 2000; 28(6):1489-97.
PMID: 10684946
PMC: 111041.
DOI: 10.1093/nar/28.6.1489.
p73 competes with p53 and attenuates its response in a human ovarian cancer cell line.
Vikhanskaya F, DIncalci M, Broggini M
Nucleic Acids Res. 1999; 28(2):513-9.
PMID: 10606650
PMC: 102516.
DOI: 10.1093/nar/28.2.513.
